Ge Shihui, Zhang Shuangli, She Linjing, Gu Tianning, Wang Shicong, Huang Xin, Wang Lanlan, Miao Mingsan
Department of Pharmacy, Henan University of Traditional Chinese Medicine, Zhengzhou, China.
Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao, Zhengzhou, China.
Front Microbiol. 2025 Aug 14;16:1623843. doi: 10.3389/fmicb.2025.1623843. eCollection 2025.
Post-stroke cognitive impairment (PSCI), a common complication following stroke, significantly impacts patients' quality of life and rehabilitation. Recent studies have highlighted the role of gut microbiota and their metabolites in modulating immunoinflammation and cognitive function via the gut-brain axis. Traditional Chinese medicine (TCM) and microbiota interventions including probiotics and fecal microbiota transplantation, have shown potential in reshaping gut microbial communities and metabolite profiles. Some studies suggest that combining these approaches via identical or related therapeutic mechanisms may yield enhanced efficacy in treating Post-Stroke Cognitive Impairment (PSCI). These findings establish a theoretical foundation for future research and clinical practice. This review systematically examines the mechanistic role of gut microbial metabolites in neuroimmune modulation and comprehensively evaluates the therapeutic potential of combined TCM and microbiota-targeted therapies for PSCI, adopting a multifactorial approach that addresses neuroinflammation, microbial dysbiosis, and metabolic dysregulation.
卒中后认知障碍(PSCI)是卒中后常见的并发症,显著影响患者的生活质量和康复。最近的研究强调了肠道微生物群及其代谢产物通过肠-脑轴调节免疫炎症和认知功能的作用。中药(TCM)以及包括益生菌和粪便微生物群移植在内的微生物群干预措施,已显示出在重塑肠道微生物群落和代谢产物谱方面的潜力。一些研究表明,通过相同或相关的治疗机制将这些方法结合起来,可能在治疗卒中后认知障碍(PSCI)方面产生更高的疗效。这些发现为未来的研究和临床实践奠定了理论基础。本综述系统地研究了肠道微生物代谢产物在神经免疫调节中的作用机制,并采用多因素方法,从神经炎症、微生物失调和代谢失调等方面,全面评估了中药与微生物群靶向联合疗法治疗PSCI的潜在疗效。